Australia markets close in 4 hours 23 minutes

Mustang Bio, Inc. (MBIO)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.5000+0.0600 (+4.17%)
At close: 04:00PM EST
1.5000 0.00 (0.00%)
After hours: 05:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.4400
Open1.4200
Bid1.4900 x 3100
Ask1.5100 x 4000
Day's range1.4000 - 1.5100
52-week range1.4000 - 5.2200
Volume757,217
Avg. volume1,126,252
Market cap140.142M
Beta (5Y monthly)1.54
PE ratio (TTM)N/A
EPS (TTM)-0.8230
Earnings date22 Mar 2022 - 28 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.80
  • GlobeNewswire

    Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

    WORCESTER, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic l

  • GlobeNewswire

    Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences

    WORCESTER, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in January 2022. Details of the events are as follows:

  • GlobeNewswire

    Mustang Bio Added to the NASDAQ Biotechnology Index

    WORCESTER, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the company has been added to the NASDAQ Biotechnology Index® (NASDAQ: NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective prior to market o